Results 171 to 180 of about 4,608 (197)

Radiation exposure to families of patients following administration of ¹⁷⁷Lu-DOTATATE for the treatment of metastatic neuroendocrine tumours. [PDF]

EJNMMI Phys
Levart D, Wicks S, Heraghty N, Kalogianni E, Mulholland N.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Peptidradiorezeptor-Therapie (PRRT)

Der Nuklearmediziner, 2021
ZusammenfassungNeuroendokrine Neoplasien (NEN) stellen ein komplexes, heterogenes Krankheitsbild dar, wobei der Primärtumorlokation meist im Gastrointestinaltrakt lokalisiert ist. Als „Orphan Disease“ sind NEN zwar selten, werden aber primär durch eine verbesserte bildgebende Diagnostik in den letzten Jahren verstärkt diagnostiziert. Hierbei spielt die
Andreas K. Buck, Constantin Lapa, Alexander Weich, Takahiro Higuchi, Natalie Hasenauer, Heribert Hänscheid, Rudolf A. Werner   +6 more
openaire   +1 more source

Pregnancy and delivery after PRRT without sequelae

Nuklearmedizin, 2018
Abstract Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues has been proven to be very useful in the management of advanced, well-differentiated neuroendocrine neoplasms (NENs). We present here the pregnancy outcome in a NEN patient, who naturally conceived and gave birth to a healthy baby, after 4 cycles of
Jingjing, Zhang, Harshad R, Kulkarni, Coline, Lehmann, Aviral, Singh, Richard P, Baum   +4 more
openaire   +2 more sources

Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations [PDF]

The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017
The purpose of this work is to implement a radiobiological model to compare different treatment schedules for Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu and 90Y. The principal radiobiological quantities were studied as a function of radionuclides, fractionation schemes, activity distribution in kidneys and tumor radiosensitivity.Clinical ...
Sarnelli, Anna, Guerriero, Francesco, Botta, Francesca, Ferrari, Mahila, Strigari, Lidia, Bodei, Lisa, D'Errico, Vincenzo, Grassi, Elisa, Fioroni, Federica, PAGANELLI, Giovanni, Orecchia, Roberto, Cremonesi, Marta   +11 more
openaire   +2 more sources

Evidence Base for the Use of PRRT

Seminars in Nuclear Medicine, 2020
The development of peptide receptor radionuclide therapy (PRRT) in disseminated neuroendocrine tumors (NETs) has been a long and protracted process. The idea was born within nuclear medicine academia but its translation to clinical practice has been marked by misunderstanding of the rigors of the processes used in drug registration.
openaire   +3 more sources

Dosimetry in PRRT

2018
Peptide receptor radionuclide therapy (PRRT) with 90Y- and 177Lu-radiolabelled peptides represents a promising option for patients with somatostatin receptor-expressing tumours. Several clinical trials have proven its efficacy and a general profile of low toxicity.
Marta Cremonesi, Mahila Ferrari, Francesca Botta   +2 more
openaire   +1 more source

Rhabdoid Papillary Meningioma Treated With 177Lu DOTATATE PRRT

Clinical Nuclear Medicine, 2015
An 18-year-old girl presented with a 3-year history of a recurrent skull base mass confirmed to be a rhabdoid papillary meningioma. The tumor was octreotide avid and metastatic to the lungs, thoracic lymph nodes, and bones, and she was referred for PRRT (peptide receptor radionuclide therapy) with 177Lu DOTATATE.
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy (PRRT)

2016
There has been tremendous progress over recent years on the development of peptide receptor radionuclide therapy (PRRT) for the treatment of a variety of cancers. In this technology, peptides radiolabeled with therapeutic radionuclides are targeted to cell-surface receptors which are often overexpressed on the membrane surface of tumor cells.
F. F. Knapp, Ashutosh Dash
openaire   +1 more source

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Best Practice & Research Clinical Gastroenterology, 2012
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). (90)Y-DOTATOC and (177)Lu-DOTATATE are the most used radiopeptides for PRRT with comparable tumour response rates (about 15 ...
Bergsma, Hendrik, Vliet, Esther, Teunissen, Jaap, Kam, BLR, de Herder, W.W., Peeters, Robin, Krenning, Eric, Kwekkeboom, Dik   +7 more
openaire   +3 more sources